Miles Congreve
About Miles Congreve
Chief Scientific Officer Miles Congreve
Miles Congreve currently holds the position of Chief Scientific Officer. In his role, he is responsible for spearheading scientific initiatives and advancing pharmaceutical research. His leadership in this capacity underscores his extensive expertise in drug discovery and development.
Education and Expertise of Miles Congreve
Miles Congreve holds a degree in biological chemistry from Leicester University. He also earned a PhD in synthetic chemistry from Cambridge University. His educational background provides a strong foundation for his work in medicinal chemistry and drug design.
Miles Congreve's Achievements in Drug Design
Miles Congreve has significantly contributed to drug design, helping to bring 20 clinically evaluated drugs to the development phase. He is a co-inventor of Kisqali (Ribociclib), a marketed treatment for breast cancer. These contributions highlight his impact on advancing medical treatments and improving patient outcomes.
Miles Congreve's Contributions to GPCR and Fragment-Based Drug Design
At Sosei Heptares, Miles Congreve pioneered Structure-Based Drug Design for G Protein-Coupled Receptors (GPCRs). His work in this area has been pivotal in the development of novel therapeutics. Additionally, he established Fragment-Based Drug Design as a new approach to small molecule lead generation during his tenure at Astex Pharmaceuticals, showcasing his innovative approach to drug discovery.
Awards and Publications by Miles Congreve
Miles Congreve is a Fellow of the Royal Society of Chemistry and has co-authored over 200 publications and patents. In 2015, he was co-recipient of the RSC Malcolm Campbell Memorial Prize, which honored his contributions to GPCR drug discovery. These accolades reflect his standing in the scientific community and his prolific output in medicinal chemistry.